Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS transfers Japan pemirolast rights

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibbhas agreed to divest Japanese manufacturing and marketing rights to the anti-allergic Pemilaston (pemirolast) to the domestic firm Alfresa Pharma. The two companies will begin joint promotional activities this month and the full transfer is due for completion next March. The change reflects a shift by BMS to other areas such as oncology, HIV and rheumatoid arthritis and an effort by Alfresa Pharma (part of the Alfresa pharmaceutical wholesaling group) to expand its existing allergy portfolio, the firms explained. Pemilaston is marketed in Japan in several adult and paediatric oral formulations and in ophthalmic form, for bronchial asthma, allergic rhinitis and conjunctivitis.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts